Drugs / TroVax
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02390063 | Jun 2015 → May 2018 | prostate cancer | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03815942 | Dec 2018 → Jun 2020 | castration-resistant prostate carcinoma | University of Oxford | Terminated | No outcome recorded |
| Phase 210 trials · 1 missed | ||||||
| Phase 2 | NCT01556841 | Nov 2013 → Apr 2019 | fallopian tube cancer, ovarian cancer, peritoneum cancer | University College, London | Completed | Missed primary |
| Phase 2 | NCT01569919 | Dec 2012 → Jun 2014 | malignant pleural mesothelioma | Wales Cancer Trials Unit | Unknown | No outcome recorded |
| Phase 2 | NCT01194960 | Aug 2010 → Mar 2013 | hormone-resistant prostate carcinoma | Oxford BioMedica | Terminated | No outcome recorded |
| Phase 2 | NCT00521274 | Aug 2007 → Jul 2008 | prostate neoplasm | The Methodist Hospital Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00445523 | May 2006 → Jan 2008 | renal cell carcinoma | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00448409 | May 2006 → Apr 2007 | prostate neoplasm | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00325507 | Nov 2005 → Jul 2008 | renal cell carcinoma | Oxford BioMedica | Completed | No outcome recorded |
| Phase 2 | NCT00083941 | Aug 2004 → Jul 2008 | renal cell carcinoma | Oxford BioMedica | Completed | No outcome recorded |
| Phase 2 | NCT00259844 | Jun 2004 → Dec 2006 | colorectal neoplasm | Cancer Research UK | Completed | No outcome recorded |
| Phase 2 | NCT00227474 | — | breast cancer | SWOG Cancer Research Network | Withdrawn | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00397345 | Sep 2006 → Dec 2009 | clear cell renal carcinoma | Oxford BioMedica | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trovax | “TroVax® consists of a highly attenuated VV (Modified Vaccinia Ankara, MVA) containing the human TAA 5T4 under regulatory control of a modified VV promoter, mH5.” NCT01556841 ↗11“Patients receive recombinant modified vaccinia Ankara-5T4 vaccine (TroVax®) intramuscularly once a month in months 1-3.” NCT00227474 ↗ “S0348: A Phase II Study of 5T4-Modified Vaccinia Ankara (MVA) Vaccine (TROVAX) in Patients With Advanced Breast Cancer” NCT00227474 ↗ “To evaluate the efficacy and safety of Trovax and GM-CSF in patients with prostate cancer.” NCT00448409 ↗ |
| Known as | 5T4-MVA | “A Phase 2 Study Immunologically Evaluating 5T4-MVA (TroVax) in Patients Undergoing Surgical Resection of Colorectal Liver Metastases” NCT00259844 ↗ |
| Known as | MVA-5T4 | “Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.” PMID 23877659 ↗ Jul 2013 |
| Modality | Vaccine | “TroVax belongs to a class of medicines called a vaccine.” NCT00083941 ↗ |
| Route | Intramuscular | “the patients will be immunised with a single intramuscular injection of 1 ml of TroVax 10x.” NCT00083941 ↗ |